Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.

Autor: Fagnano E; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Pendharkar S; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Colton M; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Jones PN; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Sallan MC; Centre for Haemato-Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Klymenko T; Department of Biosciences and Chemistry, Sheffield Hallam University, Sheffield, United Kingdom., Braun A; Centre for Haemato-Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Klein C; Roche Innovation Center Zurch, Roche Glycart AG, Schlieren, Switzerland., Honeychurch J; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Cheadle EJ; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Illidge TM; Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2023 Oct 31; Vol. 11, pp. 1270398. Date of Electronic Publication: 2023 Oct 31 (Print Publication: 2023).

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017)

Autor: Cheadle, E. J., Lipowska-Bhalla, G., Dovedi, S. J., Fagnano, E., Klein, C., Honeychurch, J., Illidge, T. M.

Publikováno v: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ' Leukemia, vol 31, no. 10, pp. 2278-2278 . DOI: 10.1038/leu.2016.352
Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ', Leukemia, vol. 31, no. 10, pp. 2278-2278 . https://doi.org/10.1038/leu.2016.352

Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c1346ea34ddd57b017f69a04f796678f
https://doi.org/10.1038/leu.2016.352

Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death.

Autor: Gisby J; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Clarke CL; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Medjeral-Thomas N; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Malik TH; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Papadaki A; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Mortimer PM; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Buang NB; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Lewis S; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Pereira M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Toulza F; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Fagnano E; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Mawhin MA; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Dutton EE; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Tapeng L; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Richard AC; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.; CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Kirk PD; MRC Biostatistics Unit, Forvie Way, University of Cambridge, Cambridge, United Kingdom.; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom., Behmoaras J; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Sandhu E; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., McAdoo SP; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Prendecki MF; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Pickering MC; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Botto M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Willicombe M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Thomas DC; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Peters JE; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Health Data Research UK, London, United Kingdom.

Publikováno v: ELife [Elife] 2021 Mar 11; Vol. 10. Date of Electronic Publication: 2021 Mar 11.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

Autor: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

Publikováno v: Leukemia; July 2017, Vol. 31 Issue: 7 p1611-1621, 11p

Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting.

Autor: Muthana M; Departments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK., Kennerley AJ; Department of Psychology, University of Sheffield, Sheffield S102RX, UK., Hughes R; Department of Oncology, University of Sheffield, Sheffield S102RX, UK., Fagnano E; Departments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK., Richardson J; Departments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK., Paul M; Departments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK., Murdoch C; Unit of Oral &Maxillofacial Medicine &Surgery, University of Sheffield, Sheffield S102RX, UK., Wright F; Departments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK., Payne C; Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London WC1E 6DD, UK., Lythgoe MF; Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London WC1E 6DD, UK., Farrow N; Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent ST4 7QB, UK., Dobson J; Department of Biomedical Engineering, University of Florida, Gainesville, Florida 32611, USA., Conner J; Virttu Biologics, Glasgow, Glasgow City G51 4TF, UK., Wild JM; Cardiovascular Sciences, University of Sheffield, Sheffield S102RX, UK., Lewis C; Department of Oncology, University of Sheffield, Sheffield S102RX, UK.

Publikováno v: Nature communications [Nat Commun] 2015 Aug 18; Vol. 6, pp. 8009. Date of Electronic Publication: 2015 Aug 18.